[Treatment with the peptide bioregulator retinalamine in patients with tuberculosis of the organ of vision].
The efficacy of the bioregulator retinalamine in the complex pathogenetic treatment was studied in patients with ocular tuberculosis. Ninety-seven patients (132 eyes) with tuberculous chorioretinitis in the inactive phase were examined. According to the treatment option, the patients were divided into 2 groups: 1) a study group and 2) a control one. Parabulbar injections of retinalamine were made in the study group. In the control one, conventional treatment was used as parabulbar injections of emoxypine (a synthetic antioxidant). As compared with the traditional treatment, retinalamine used in the treatment of patients with tuberculous choriorenitis without clinical signs was ascertained to substantially to improve retinal functional activity, as manifested as a 66.3% increase in visual acuity, a reduction in abnormal scotomas in the field of vision in 72.7% of cases, and electrophysiological parameters as the enhanced activity of the first retinal neuron in 88.3% of case, as shown by the ganz-feld electroretinogram and in 14.3% of cases, as indicated by macular electroretinogram. The higher activity of the second retinal neuron was recorded in 89.6 and 58.4% of cases, as seen in the ganz-feld and macular electroretinograms, respectively. Moreover, inclusion of retinalamine into the complex treatment in patients with tuberculous chorioretinitis slowed down the maturation rate of concomitant age-related cataract and prevented diminished vision in 97.8, 95.6, 66.7, and 53.3% of cases within the first, second, third, and fourth years after treatment, respectively.